186 related articles for article (PubMed ID: 25892092)
1. The long-term efficacy and safety of immunosuppressive therapy on the progression of IgA nephropathy: a meta-analysis of controlled clinical trials with more than 5-year follow-up.
Tian L; Shao X; Xie Y; Wang L; Wang Q; Che X; Ni Z; Mou S
Expert Opin Pharmacother; 2015 Jun; 16(8):1137-47. PubMed ID: 25892092
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of immunosuppressive treatment in IgA nephropathy: a meta-analysis of randomized controlled trials.
Zhang Z; Yang Y; Jiang SM; Li WG
BMC Nephrol; 2019 Aug; 20(1):333. PubMed ID: 31455248
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
Manno C; Torres DD; Rossini M; Pesce F; Schena FP
Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive therapy in patients with IgA nephropathy.
Peters HP; van den Brand JA; Berger SP; Wetzels JF
Neth J Med; 2015 Jul; 73(6):284-9. PubMed ID: 26228193
[TBL] [Abstract][Full Text] [Related]
5. Tonsillectomy for IgA nephropathy: a meta-analysis.
Liu LL; Wang LN; Jiang Y; Yao L; Dong LP; Li ZL; Li XL
Am J Kidney Dis; 2015 Jan; 65(1):80-7. PubMed ID: 25446024
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of immunosuppressive therapies in the treatment of high-risk IgA nephropathy: A network meta-analysis.
Liu T; Wang Y; Mao H; Yang L; Zhan Y
Medicine (Baltimore); 2021 Feb; 100(8):e24541. PubMed ID: 33663060
[TBL] [Abstract][Full Text] [Related]
7. Combined Immunosuppressive Treatment May Improve Short-Term Renal Outcomes in Chinese Patients with Advanced IgA Nephropathy.
Tan L; Tang Y; Peng W; Mathew BS; Qin W
Kidney Blood Press Res; 2018; 43(4):1333-1343. PubMed ID: 30099439
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of IgA nephropathy with chronic renal failure].
Pozzi C
G Ital Nefrol; 2008; 25 Suppl 44():83-7. PubMed ID: 19048591
[TBL] [Abstract][Full Text] [Related]
9. Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.
Rauen T; Fitzner C; Eitner F; Sommerer C; Zeier M; Otte B; Panzer U; Peters H; Benck U; Mertens PR; Kuhlmann U; Witzke O; Gross O; Vielhauer V; Mann JFE; Hilgers RD; Floege J
J Am Soc Nephrol; 2018 Jan; 29(1):317-325. PubMed ID: 29042456
[TBL] [Abstract][Full Text] [Related]
10. [Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].
Pozzi C; Del Vecchio L; Locatelli F
G Ital Nefrol; 2002; 19(5):523-8. PubMed ID: 12439840
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of immunosuppression treatment on IgA nephropathy: a systematic review and meta-analysis.
Chen N; Huang HL; Yang YD
Ann Palliat Med; 2021 Nov; 10(11):11830-11839. PubMed ID: 34872307
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of IgA nephropathy with minimal change disease: a comparison between patients with and without minimal change disease.
Li XW; Liang SS; Le WB; Cheng SQ; Zeng CH; Wang JQ; Liu ZH
J Nephrol; 2016 Aug; 29(4):567-73. PubMed ID: 26537358
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria.
Zhong Z; Tang Y; Tan J; Tan L; Pei G; Qin W
Int Urol Nephrol; 2021 Jan; 53(1):121-127. PubMed ID: 32944888
[TBL] [Abstract][Full Text] [Related]
14. Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy.
Min L; Wang Q; Cao L; Zhou W; Yuan J; Zhang M; Che X; Mou S; Fang W; Gu L; Zhu M; Wang L; Yu Z; Qian J; Ni Z
Oncotarget; 2017 Jul; 8(29):48375-48384. PubMed ID: 28415636
[TBL] [Abstract][Full Text] [Related]
15. Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria.
Pei G; Tan J; Tang Y; Tan L; Zhong Z; Zhou L; Chen C; Qin W
Medicine (Baltimore); 2020 Jun; 99(24):e20513. PubMed ID: 32541473
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive agents in the treatment of IgA nephropathy: A meta-analysis of clinical randomized controlled literature.
Zheng J; Gong X; Wu Z
Niger J Clin Pract; 2020 Apr; 23(4):437-449. PubMed ID: 32246648
[TBL] [Abstract][Full Text] [Related]
17. The prognostic effect of immunosuppressive therapy in IgA nephropathy with stage 3 or 4 chronic kidney disease.
Yang X; Ma F; Bai M; Wang Y; Jia Q; Dong R; Liu C; Sun S
Ren Fail; 2021 Aug; 43(1):1180-1187. PubMed ID: 34376108
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis.
Song YH; Cai GY; Xiao YF; Wang YP; Yuan BS; Xia YY; Wang SY; Chen P; Liu SW; Chen XM
BMC Nephrol; 2017 Feb; 18(1):61. PubMed ID: 28193247
[TBL] [Abstract][Full Text] [Related]
19. Corticosteroid therapy in IgA nephropathy.
Lv J; Xu D; Perkovic V; Ma X; Johnson DW; Woodward M; Levin A; Zhang H; Wang H;
J Am Soc Nephrol; 2012 Jun; 23(6):1108-16. PubMed ID: 22539830
[TBL] [Abstract][Full Text] [Related]
20. Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation.
Shen XH; Liang SS; Chen HM; Le WB; Jiang S; Zeng CH; Zhou ML; Zhang HT; Liu ZH
J Nephrol; 2015 Aug; 28(4):441-9. PubMed ID: 25585823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
